1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. TORRENT PHARMACEUTICALS LTD.
Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM | BSE: 500420

Torrent Pharma Live Share Price Today, Share Analysis and Chart

Expensive Performer
BasketIn 1 Starfolio Basket
aboutTorrent Pharmaceuticals Ltd. (Torrent Pharma) is a leading Indian pharmaceutical company and the flagship entity of the Torrent Group. The company specializes in niche marketing and has established a significant presence in therapeutic segments inclu... Read More
ANDA Approvals
Ask AI about Torrent Pharma
4613.4033.40(0.73%)
499.1K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
53.8 / 100
Expensive PerformerThese stocks have medium quality and momentum.Their expensive valuations suggest cautionView SimilarEmbed DVM
Analyst Price Target
-

14

S

11

W

9

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

11Positive12Negative

47.8%Pass in checklist

045
55
100

PE Valuation Check

Right Now
Overvalued
-13.2%
1 Year Forward
Fairly Valued
-0.4%
INSIGHTTorrent Pharma is overvalued at current PE, but fairly valued on future earnings estimates

Torrent Pharma Stock Price Analysis

Day Price Range

0.7% 1 Day return
4613.4 (LTP)
4,5324,672
LowHigh

Week Price Range

2.0% 1 Week return
4613.4 (LTP)
4,466.84,672
LowHigh

Month Price Range

-5.7% 1 Month return
4613.4 (LTP)
4,466.84,935
LowHigh

52 Week Price Range

28.1% 1 Year return
4613.4 (LTP)
3,532.65,250
LowHigh
View full Price History/Seasonality

Torrent Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Torrent Pharma's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
63.9
AVG. ESTIMATE
65.1
LOW ESTIMATE
57.9
HIGH ESTIMATE
74.2
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 1.8% in FY27

Consensus Recommendation

28 ANALYST Recommendations
BUY

The consensus recommendation from 28 analysts for Torrent Pharma is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Torrent Pharma Technical Analysis

Torrent Pharma EMA & SMA

Neutral0
4 bullish, 4 bearish
Bullish4
Bearish4
5 Day4588.6
10 Day4594.2
12 Day4601.9
20 Day4641.8
26 Day4670.8
50 Day4736.2
100 Day4707.8
200 Day4502.1

Torrent Pharma Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202667.9%
Week64.0%
Month62.2%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Torrent Pharma Resistance and Support

4605.80
Pivot
First Resistance4679.6
Second Resistance4745.8
Third Resistance4819.6
First Support4539.6
Second Support4465.8
Third Support4399.6
Day RSI44.7
Day MACD-68.9
Day MFI43.6
Day MACD Signal Line-77.8

Torrent Pharma Beta

1 Month0.5
1 Year0.3
3 Month0.4
3 Year0.4

Torrent Pharma Price Change Analysis

↓-5.7%
Over 1 Month
LowHigh
4466.84935
↓-5.3%
Over 3 Months
LowHigh
4466.85250
↑9.0%
Over 6 Months
LowHigh
4146.15250
↑28.1%
Over 1 Year
LowHigh
3532.65250
All Technicals →

Torrent Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Torrent Investments Limited (Formerly Known As Torrent Investments Private Limited)Promoter231,183,40060.8 %
Nps TrustDii8,836,0642.3 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Torrent Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
UBS PRINCIPAL CAPITAL ASIA LIMITEDBlockSell23 Jan 20253252.1044,810NSE
UBS AGBlockPurchase23 Jan 20253252.1044,810NSE
TORRENT INVESTMENTS PRIVATE LIMITEDBulkSell30 Oct 20243103.074,972,020BSE
TORRENT INVESTMENTS PRIVATE LIMITEDBulkSell30 Oct 20243104.404,972,020BSE
SEB FUND 3 SEB PENSION FUNDBlockSell07 Mar 20242691.2063,294NSE
SEB ASIENFOND EX JAPANBlockPurchase07 Mar 20242691.2063,294NSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 20242507.05474,629BSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 20242507.0555,561BSE
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUNDBlockPurchase25 Jan 20242507.053,883BSE
MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUNDBlockPurchase25 Jan 20242507.0547,322BSE
All deals
All insider trades

Torrent Pharma Corporate Actions

Torrent Pharma Dividend history and yield

Torrent Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Torrent Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
129 May 2026
9FINAL29 May 2026Equity Share
218 Feb 2026
29INTERIM19 Feb 2026Equity Share
320 Jun 2025
6FINAL20 Jun 2025Equity Share
431 Jan 2025
26INTERIM01 Feb 2025Equity Share
521 Jun 2024
6FINAL21 Jun 2024Equity Share

Torrent Pharma Bonus shares

Torrent Pharma bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
108 Jul 2022
1:111 Jul 2022
223 Jul 2013
1:124 Jul 2013
320 Feb 2006
1:127 Feb 2006

Torrent Pharma Board Meetings

Torrent Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
123 Oct 2026
Quarterly Results-
230 Jul 2026
Quarterly Results-
322 May 2026
Audited Results, Dividend & Fund Raising-
413 Feb 2026
Quarterly Results & Interim Dividend-
505 Jan 2026
OthersTo consider Fund Raising

Torrent Pharma Stock Split

Torrent Pharma stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
120 Feb 2006
10527 Feb 2006
All Corporate Actions

Torrent Pharma Research Reports

Torrent Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
123 Oct 2026Motilal Oswal
Target
49704524.4Neutral9.85%1.97%pdf
230 Jul 2026Motilal Oswal
Target
47304872.1Neutral-2.92%-5.31%pdf
330 Jul 2026ICICI Securities Limited
Target
49254872.1Hold1.09%-5.31%pdf
430 Jun 2026ICICI Securities Limited
Target
48004640.8Hold3.43%-0.59%pdf
524 Jun 2026Geojit BNP Paribas
Target
48984516.2Hold8.45%2.15%pdf
All Reports of Torrent

Torrent Pharma Corporate Filings

Torrent Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
29 Oct 2026
Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter and half year ended 30th September, 2026
PDF
23 Oct 2026
Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Recording Link of Analyst call - Q2 Results
PDF
23 Oct 2026
Torrent Pharmaceuticals Results Earnings Call for Q2FY27
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q2FY27 Performance and Outlook. Listen to the full earnings transcript.
PDF
23 Oct 2026
Q2FY27 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Pharmaceuticals company Torrent Pharmaceuticals announced Q2FY27 results Consolidated Financial Highlights: Total revenue from operations for Q2FY27 stands at Rs 4,979 crore, indicating a QoQ increase of 1.18% from Rs 4,921 crore in Q1FY27 and a YoY increase of 50.79% from Rs 3,302 crore in Q2FY26. For H1FY27, total revenue from operations stands at Rs 9,900 crore, indicating a YoY increase of 52.78% from Rs 6,480 crore in H1FY26. Total income for Q2FY27 stands at Rs 4,969 crore, demonstrating a QoQ increase of 1.22% compared to Rs 4,909 crore in Q1FY27 and a YoY increase of 51.73% from Rs 3,275 crore in Q2FY26. For H1FY27, total income stands at Rs 9,878 crore, showcasing a YoY increase of 53.96% from Rs 6,416 crore in H1FY26. Profit before tax (PBT) for Q2FY27 stands at Rs 737 crore, displaying a QoQ increase of 0.55% against Rs 733 crore in Q1FY27 and a YoY decrease of 6.83% from Rs 791 crore in Q2FY26. For H1FY27, profit before tax stands at Rs 1,470 crore, registering a YoY decrease of 3.86% from Rs 1,529 crore in H1FY26. Net profit for the period (PAT) for Q2FY27 stands at Rs 534 crore, reflecting a QoQ decrease of 5.65% from Rs 566 crore in Q1FY27 and a YoY decrease of 9.64% from Rs 591 crore in Q2FY26. For H1FY27, net profit stands at Rs 1,100 crore, noting a YoY decrease of 3.42% from Rs 1,139 crore in H1FY26. Earnings per share (EPS) basic and diluted for Q2FY27 stands at Rs 14.05, representing a QoQ decrease of 5.51% from Rs 14.87 in Q1FY27 and a YoY decrease of 19.48% from Rs 17.45 in Q2FY26. For H1FY27, basic and diluted EPS stands at Rs 28.92, showing a YoY decrease of 14.03% from Rs 33.64 in H1FY26. Standalone Financial Highlights: Total revenue from operations for Q2FY27 stands at Rs 4,145 crore, representing a QoQ decline of 0.31% from Rs 4,158 crore in Q1FY27 and a YoY increase of 50.07% from Rs 2,762 crore in Q2FY26. For H1FY27, total revenue from operations stands at Rs 8,303 crore, showcasing a YoY increase of 54.39% from Rs 5,378 crore in H1FY26. Total income for Q2FY27 stands at Rs 4,134 crore, displaying a QoQ decrease of 0.07% compared to Rs 4,137 crore in Q1FY27 and a YoY increase of 51.15% from Rs 2,735 crore in Q2FY26. For H1FY27, total income stands at Rs 8,271 crore, representing a YoY increase of 54.71% from Rs 5,346 crore in H1FY26. Profit before tax (PBT) for Q2FY27 stands at Rs 676 crore, representing a QoQ growth of 1.96% from Rs 663 crore in Q1FY27 and a YoY decline of 16.13% against Rs 806 crore in Q2FY26. For H1FY27, profit before tax stands at Rs 1,339 crore, demonstrating a YoY decline of 13.50% from Rs 1,548 crore in H1FY26. Net profit for the period (PAT) for Q2FY27 stands at Rs 498 crore, registering a QoQ growth of 1.22% from Rs 492 crore in Q1FY27 and a YoY decrease of 16.58% from Rs 597 crore in Q2FY26. For H1FY27, net profit stands at Rs 990 crore, showing a YoY decrease of 13.76% from Rs 1,148 crore in H1FY26. Earnings per share (EPS) basic and diluted for Q2FY27 stands at Rs 13.09, showing a QoQ growth of 1.16% from Rs 12.94 in Q1FY27 and a YoY decrease of 25.79% against Rs 17.64 in Q2FY26. For H1FY27, basic and diluted EPS stands at Rs 26.03, representing a YoY decrease of 23.26% from Rs 33.92 in H1FY26. Result PDF
PDF
23 Oct 2026
Torrent Pharmaceuticals Ltd - 500420 - Board Meeting Outcome for Outcome Of Board Meeting Dated 23-Oct-26
Outcome of Board Meeting dated 23-Oct-26
PDF
VIEW ALL

Torrent Pharma DocumentsAsk MarketMind AI

Torrent Pharma Earnings Call

Torrent Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
29 Oct 2026Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
23 Oct 2026Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
23 Oct 2026Torrent Pharmaceuticals Results Earnings Call for Q2FY27AudioVideo
04 Aug 2026Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
30 Jul 2026Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
view all

Torrent Pharma Annual Reports

Torrent Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Torrent Pharma Credit Ratings

Torrent Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
06 Oct 2026india ratingsIndia Ratings Revises Outlook on Torrent Pharmaceuticals and its NCDs to Positive; Affirms ‘IND AA+’; Rates Additional CPLink
20 Jul 2026icra ratingsTorrent Pharmaceuticals LimitedChange in limitsLink
04 Jan 2026icra ratingsTorrent Pharmaceuticals LimitedRatings reaffirmed; [ICRA]A1+ assigned for fresh CPs of Rs. 1,500.00 crore and rating reaffirmed and withdrawn for NCDs of Rs. 1,642.84 croreLink
01 Jan 2026india ratingsIndia Ratings Assigns Torrent Pharmaceuticals’ Proposed CP ‘IND A1+’; Affirms Existing RatingsLink
05 Oct 2025india ratingsIndia Ratings Assigns Torrent Pharmaceuticals’s Additional NCDs ‘IND AA+’/Stable; Affirms Existing RatingsLink

Torrent Pharma Investor Presentations

Torrent Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
22 May 2026Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 Feb 2026Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
07 Nov 2025Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
28 Jul 2025Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Jun 2025Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Torrent Pharma - Company Profile

Torrent Pharma Management Structure

Torrent Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Hasmukh PatelChief Operating Officer-Mar 26
Amal KelshikarExecutive Director(India Business Unit)-Mar 26
Sunil NadkarniExecutive Director(Product Development.)-Mar 26
Sushil JaiswalExecutive Director(Quality)-Mar 26
Geena MalhotraChief Technology Officer-Mar 26
Sudhir MenonExecutive Director(Finance),Chief Financial Officer-Mar 26
CHINTAN MAHESHKUMAR TRIVEDICompany Secretary,Compliance Officer-Mar 26

Torrent Pharma Board of Directors

Torrent Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Samir MehtaChairman/ED & CEO3600.4Mar 26
Aman MehtaED / MD / Promoter1881.84Mar 26
Nayantara BaliIndependent Non Exe. Director76Mar 26
Nikhil KhattauIndependent Non Exe. Director76Mar 26
Manish ChoksiLead Independent Non Executive Director54Mar 26
Jindal MehtaNon-Exec & Non-Independent Dir-Mar 26
Chintan M. TrivediCompany Sec. & Compli. Officer-Mar 26
Sudhir MehtaChairman Emeritus-Mar 26

Torrent Pharma Brands

Brands owned by Torrent Pharma

LOGOBRAND NAME
D-360
Shelcal-250
Allenil
Levmore
LOGOBRAND NAME
Torflash 60K
Torflash
Shelcal -m
Shelcal-HD12
LOGOBRAND NAME
Shelcal-500
One Up Gold D
Elcafort
Cobasoft OD
LOGOBRAND NAME
B Long
Cranbe
Cyclospasmol
Asthafen Syrup
Website: www.torrentpharma.com

About the company - Business Profile

Torrent Pharmaceuticals Ltd. (Torrent Pharma) is a leading Indian pharmaceutical company and the flagship entity of the Torrent Group. The company specializes in niche marketing and has established a significant presence in therapeutic segments including cardiovascular, central nervous system, gastrointestinal, and vitamins minerals nutrients. Torrent Pharma operates globally with a focus on specialty-driven markets, ranking among the top pharmaceutical companies in India, Brazil, and Germany.

The company follows a specialty-focused business model, with approximately 76% of its Indian revenues derived from chronic and sub-chronic therapies. Its operational infrastructure includes eight manufacturing facilities, five of which are USFDA approved, and a dedicated R&D center employing over 750 scientists.

Key Points

  • Key Facts:
    • Founded: 1972.
    • Headquarters: Ahmedabad, Gujarat, India.
    • Parent Company: Torrent Group (Total group revenue ~₹45,000 crores).
    • Stock Listing: BSE (500420) and NSE (TORNTPHARM).
    • Market Capitalization: ₹1,09,200 crores (as of March 31, 2025).
  • Operations and Resources:
    • Manufacturing: Operates 8 manufacturing facilities; 5 are USFDA approved.
    • R&D: Employs 750+ scientists with a focus on generic formulation development.
    • Global Reach: Presence in over 50 countries, with direct operations in the USA, Brazil, Germany, Mexico, and several Asian markets.
  • Market and Significance:
    • Rankings: Ranked 7th in the Indian Pharmaceutical Market (IPM). It holds the No. 1 position among Indian pharma companies in Brazil and Germany.
    • Therapeutic Leadership: Ranked 6th in the combined chronic/sub-chronic segment in India. 21 brands are featured in the Top 500 brands of the IPM.
  • Revenue Breakdown (FY 2024-25):
    • Total Revenue: ₹11,516 crores (7% growth over FY 2023-24).
    • Geographical Share:
      • India: ₹6,393 crores (55% of total revenue, 13% YoY growth).
      • USA: ₹1,100 crores (10% share, 2% YoY growth).
      • Germany: ₹1,139 crores (10% share, 6% YoY growth).
      • Brazil: ₹1,100 crores (10% share, -2% YoY growth).
      • Others: ₹1,784 crores (15% share).
  • Key Products and Business Units:
    • Segments: Cardiovascular (CV), Central Nervous System (CNS), Gastro-Intestinal (GI), Vitamins Minerals Nutrients (VMN), and Cosmo-Dermatology.
    • Brand Strength: 18 brands have annual revenues exceeding ₹100 crores.
    • Recent Acquisition: In 2025, the company entered into a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited.
  • Employee Count and Attrition:
    • As of March 31, 2024, the company employed 14,066 permanent employees.
    • Gender diversity: 92% male and 8% female among permanent staff.
  • Strategic Initiatives and Outlook:
    • Specialty Focus: Continuous focus on expanding the chronic and sub-chronic portfolio in India.
    • Acquisition Strategy: Leveraging inorganic growth, as seen with the J.B. Chemicals acquisition to strengthen its market position.
    • Cost Management: Maintaining high operating margins, with an Operating EBITDA of ₹3,721 crores in FY 2024-25 (32% margin).

References

  1. Annual Report May 2025
  2. Annual Report May 2024
  3. Result Nov 2025
  4. Investor Presentation Feb 2026
  5. Result Feb 2026

Torrent Pharma FAQ

Torrent Pharma today is trading in the green, up by 0.73% at ₹4,613.4.
Torrent Pharma is currently trading up 0.73% on an intraday basis. In the past week the stock rose 1.97%. Stock has been down 5.31% in the past quarter and rose 28.06% in the past year. You can view this in the share price history/seasonality section.
Torrent Pharma is listed on NSE with the ticker TORNTPHARM and on BSE as 500420. It's currently trading on NSE at a share price of ₹4,613.4 and on BSE with a share price of ₹4,635.15.
The market cap of Torrent Pharma is ₹175,478.93 Cr. as of Oct 30, 2026.
Torrent Pharma announced a FINAL dividend of 180% which equals ₹9 in May 29, 2026.The last three ex-dates for Torrent Pharma were Feb 18, 2026, Jun 20, 2025 and Jan 31, 2025. To view the full dividend history of Torrent Pharma click here.
Torrent Pharma has undergone 1 stock split and announced bonus shares 3 times since its BSE/NSE listing. The latest announcement for Torrent Pharma stock split was on Feb 20, 2006 at a ratio of 10:5 and the last bonus share announcement was on Jul 08, 2022 at a ratio of 1:1.
Torrent Pharma reported ₹4,969 Cr. in revenue, ₹534 Cr. in net profit, and ₹1,646 Cr. in EBITD as of Oct 23, 2026 for Q2 FY26-27.
According to the predictions of 28 analysts, the share price prediction for Torrent Pharma is ₹5,472.79 with an upside of 19%.
The PE ratio of Torrent Pharma is 82.62 as of Oct 30, 2026.
The PB ratio of Torrent Pharma is 19.55 as of Oct 30, 2026.
You can view the latest analyst reports on the Torrent Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×